Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (38)
Angelina Isabella Mellentin, Sara Wallhed Finn, Lotte Skøt, Daniel Thaysen-Petersen, Nicolaj Mistarz, Anders Fink-Jensen & Dorthe Grüner Nielsen. (2023) The effectiveness of oxytocin for treating substance use disorders:A systematic review of randomized placebo-controlled trials. Neuroscience & Biobehavioral Reviews 151, pages 105185.
Crossref
Crossref
Stephen Lee-Cheong, Sacha A. Ludgate, Tanisse C.M. Epp & Christian G. Schütz. (2023) The effectiveness of oxytocin in the treatment of stimulant use disorders: a systematic review. Behavioural Pharmacology.
Crossref
Crossref
Melinda Hersey, Amanda K. Bacon, Lydia G. Bailey, Mary R. Lee, Andy Y. Chen, Lorenzo Leggio & Gianluigi Tanda. (2022) Oxytocin receptors mediate oxytocin potentiation of methylphenidate‐induced stimulation of accumbens dopamine in rats. Journal of Neurochemistry 164:5, pages 613-623.
Crossref
Crossref
Olga Wronikowska-Denysiuk, Weronika Mrozek & Barbara Budzyńska. (2023) The Role of Oxytocin and Vasopressin in Drug-Induced Reward—Implications for Social and Non-Social Factors. Biomolecules 13:3, pages 405.
Crossref
Crossref
Kathryn J. Schunke, Matthew W. Kay & David Mendelowitz. 2023. Cardiovascular Neuroendocrinology. Cardiovascular Neuroendocrinology
217
232
.
Giuseppe Giannotti, Francesca Mottarlini, Jasper A. Heinsbroek, Mitchel R. Mandel, Morgan H. James & Jamie Peters. (2022) Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking. Translational Psychiatry 12:1.
Crossref
Crossref
Jane E. Joseph, Nicholas Bustos, Kathleen Crum, Julianne Flanagan, Nathaniel L. Baker, Karen Hartwell, Megan Moran Santa-Maria, Kathleen Brady & Aimee McRae-Clark. (2022) Oxytocin moderates corticolimbic social stress reactivity in cocaine use disorder and healthy controls. Comprehensive Psychoneuroendocrinology 11, pages 100150.
Crossref
Crossref
Sarah J. Baracz, Katherine J. Robinson, Amanda L. Wright, Anita J. Turner, Iain S. McGregor, Jennifer L. Cornish & Nicholas A. Everett. (2022) Oxytocin as an adolescent treatment for methamphetamine addiction after early life stress in male and female rats. Neuropsychopharmacology 47:8, pages 1561-1573.
Crossref
Crossref
Andrew Lofts, Fahed Abu-Hijleh, Nicolette Rigg, Ram K. Mishra & Todd Hoare. (2022) Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs. CNS Drugs 36:7, pages 739-770.
Crossref
Crossref
Mariana Rae, Mariana Lemos Duarte, Ivone Gomes, Rosana Camarini & Lakshmi A. Devi. (2021) Oxytocin and vasopressin: Signalling, behavioural modulation and potential therapeutic effects. British Journal of Pharmacology 179:8, pages 1544-1564.
Crossref
Crossref
Wilfrid Noël Raby, Matthew Heller, Demetrios Milliaressis, C. Jean Choi, Cale Basaraba, Martina Pavlicova, Daniel M. Alschuler, Frances R. Levin, Sarah Church & Edward V. Nunes. (2022) Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study. Drug and Alcohol Dependence Reports 2, pages 100016.
Crossref
Crossref
Christopher S. Stauffer, Tyler E. Morrison, Nathan K. Meinzer, David Leung, Jessica Buffington, Evan G. Sheh, Thomas C. Neylan, Aoife O'Donovan & Joshua D. Woolley. (2022) Effects of oxytocin administration on fear-potentiated acoustic startle in co-occurring PTSD and alcohol use disorder: A randomized clinical trial. Psychiatry Research 308, pages 114340.
Crossref
Crossref
Christopher S. Stauffer, Salem Samson, Alex Hickok, William F. Hoffman & Steven L. Batki. (2022) Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial. Frontiers in Psychiatry 12.
Crossref
Crossref
Matthew W. Kay, Vivek Jain, Gurusher Panjrath & David Mendelowitz. (2022) Targeting Parasympathetic Activity to Improve Autonomic Tone and Clinical Outcomes. Physiology 37:1, pages 39-45.
Crossref
Crossref
Ben Houghton, Christos Kouimtsidis, Theodora Duka, Yannis Paloyelis & Alexis Bailey. (2021) Can intranasal oxytocin reduce craving in automated addictive behaviours? A systematic review. British Journal of Pharmacology 178:21, pages 4316-4334.
Crossref
Crossref
Erin L. Martin, Elizabeth M. Doncheck, Carmela M. Reichel & Aimee L. McRae-Clark. (2021) Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking. Neurobiology of Stress 15, pages 100364.
Crossref
Crossref
Katrine Melby, Rolf W Gråwe, Trond O Aamo, Eva Skovlund & Olav Spigset. (2021) Efficacy of Self-Administered Intranasal Oxytocin on Alcohol Use and Craving After Detoxification in Patients With Alcohol Dependence. A Double-Blind Placebo-Controlled Trial. Alcohol and Alcoholism 56:5, pages 565-572.
Crossref
Crossref
Xiaohang Che, Jialing Cai, Yueyang Liu, Tianyu Xu, Jingyu Yang & Chunfu Wu. (2021) Oxytocin signaling in the treatment of drug addiction: Therapeutic opportunities and challenges. Pharmacology & Therapeutics 223, pages 107820.
Crossref
Crossref
Fabrizio Sanna & Maria Antonietta De Luca. (2021) The potential role of oxytocin in addiction: What is the target process?. Current Opinion in Pharmacology 58, pages 8-20.
Crossref
Crossref
Danielle K. PattersonDavid PollockC. Sue CarterJoanna E. Chambers. (2021) Treating Opioid Use Disorder in Peripartum Mothers: A Look at the Psychodynamics, Neurobiology, and Potential Role of Oxytocin. Psychodynamic Psychiatry 49:1, pages 48-72.
Crossref
Crossref
Carmen Ferrer-Pérez, Marina D. Reguilón, José Miñarro & Marta Rodríguez-Arias. (2021) Oxytocin Signaling as a Target to Block Social Defeat-Induced Increases in Drug Abuse Reward. International Journal of Molecular Sciences 22:5, pages 2372.
Crossref
Crossref
Vivek Jain, Shawn Kimbro, Grant Kowalik, Ivana Milojevic, N. Maritza Dowling, Anne Lloyd Hunley, Kelsey Hauser, David C. Andrade, Rodrigo Del Rio, Matthew W. Kay & David Mendelowitz. (2020) Intranasal oxytocin increases respiratory rate and reduces obstructive event duration and oxygen desaturation in obstructive sleep apnea patients: a randomized double blinded placebo controlled study. Sleep Medicine 74, pages 242-247.
Crossref
Crossref
Christopher S. Stauffer, Jenna M. Moschetto, Scott McKernan, Nathan Meinzer, Chavy Chiang, Rachel Rapier, Elaine Hsiang, Jerika Norona, Brian Borsari & Joshua D. Woolley. (2020) Oxytocin-enhanced group therapy for methamphetamine use disorder: Randomized controlled trial. Journal of Substance Abuse Treatment 116, pages 108059.
Crossref
Crossref
Sean B Dolan, Meredith S Berry, Patrick S Johnson & Matthew W Johnson. (2019) Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin. Journal of Psychopharmacology 34:3, pages 336-347.
Crossref
Crossref
Sarah J. Baracz, Nicholas A. Everett & Jennifer L. Cornish. (2020) The impact of early life stress on the central oxytocin system and susceptibility for drug addiction: Applicability of oxytocin as a pharmacotherapy. Neuroscience & Biobehavioral Reviews 110, pages 114-132.
Crossref
Crossref
Katrine Melby, Ole B. Fasmer, Tone E. Henriksen, Rolf W. Gråwe, Trond O. Aamo & Olav Spigset. (2020) Actigraphy assessment of motor activity and sleep in patients with alcohol withdrawal syndrome and the effects of intranasal oxytocin. PLOS ONE 15:2, pages e0228700.
Crossref
Crossref
Marilyn Horta, Kathryn Kaylor, David Feifel & Natalie C. Ebner. (2020) Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review. Neuroscience & Biobehavioral Reviews 108, pages 1-23.
Crossref
Crossref
Lane Strathearn, Carol E. Mertens, Linda Mayes, Helena Rutherford, Purva Rajhans, Guifeng Xu, Marc N. Potenza & Sohye Kim. (2019) Pathways Relating the Neurobiology of Attachment to Drug Addiction. Frontiers in Psychiatry 10.
Crossref
Crossref
Mary K. Estes, Timothy G. Freels, William T. Prater & Deranda B. Lester. (2019) Systemic oxytocin administration alters mesolimbic dopamine release in mice. Neuroscience 408, pages 226-238.
Crossref
Crossref
Stephanie C. Reed, Margaret Haney, Jeanne Manubay, Bianca R. Campagna, Brian Reed, Richard W. Foltin & Suzette M. Evans. (2019) Sex differences in stress reactivity after intranasal oxytocin in recreational cannabis users. Pharmacology Biochemistry and Behavior 176, pages 72-82.
Crossref
Crossref
Brian J. Sherman & Aimee L. McRae-Clark. 2019. Cannabis Use Disorders. Cannabis Use Disorders
207
211
.
Panos Zanos, Polymnia Georgiou, Carol Weber, Fiona Robinson, Christos Kouimtsidis, Ramin Niforooshan & Alexis Bailey. (2017) Oxytocin and opioid addiction revisited: old drug, new applications. British Journal of Pharmacology 175:14, pages 2809-2824.
Crossref
Crossref
Shih-Hsien Lin, Po See Chen, Lan-Ting Lee, Sheng-Yu Lee, Hsin Chun Tsai, Wei Tseng Chen, Kao Chin Chen, I. Hui Lee, Ru-Band Lu & Yen Kuang Yang. (2018) The Association between the Level of Plasma Oxytocin and Craving among Former Heroin Users. European Addiction Research 24:2, pages 71-78.
Crossref
Crossref
Michael T. Bowen & Inga D. Neumann. (2017) Rebalancing the Addicted Brain: Oxytocin Interference with the Neural Substrates of Addiction. Trends in Neurosciences 40:12, pages 691-708.
Crossref
Crossref
Brian J. Sherman, Nathaniel L. Baker & Aimee L. McRae-Clark. (2017) Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. Psychiatry Research 249, pages 318-320.
Crossref
Crossref
Cort A. Pedersen. 2017. The Role of Neuropeptides in Addiction and Disorders of Excessive Consumption. The Role of Neuropeptides in Addiction and Disorders of Excessive Consumption
239
274
.
Michael T. Bowen & Inga D. Neumann. 2018. Behavioral Pharmacology of Neuropeptides: Oxytocin. Behavioral Pharmacology of Neuropeptides: Oxytocin
269
287
.
Sarah J. Baracz & Jennifer L. Cornish. (2016) The neurocircuitry involved in oxytocin modulation of methamphetamine addiction. Frontiers in Neuroendocrinology 43, pages 1-18.
Crossref
Crossref